Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

ABSTRACT:

Background

Adenovirus serotype 26 (Ad26) has been developed as a novel candidate vaccine vector for human immunodeficiency virus type 1 (HIV-1) and other pathogens. The primary safety and immunogenicity data from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the first-in-human evaluation of a prototype Ad26 vector-based vaccine expressing clade A HIV-1 Env (Ad26.ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans.

Methods

Samples from the IPCAVD 001 trial were used for humoral and cellular immunogenicity assays.

Results

We observed a dose-dependent expansion of the magnitude, breadth, and epitopic diversity

SUBMITTER: Barouch DH 

PROVIDER: S-EPMC3532832 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature